Gemcitabine/nab‐paclitaxel for pediatric relapsed/refractory sarcomas

Abstract

Gemcitabine/nab-paclitaxel is a relatively safe regimen with mainly hematologic toxicities. It offers a well-tolerated, palliative option providing clinical benefit in a subset of patients. A phase I trial of this combination is underway.